Assessment of the circulating mir-222 expression level in under treatment epileptic patients as a non-invasive biomarker of PCOs

Background: Epilepsy is a prevalent chronic neurologic disorder characterized by recurrent unprovoked seizures. However, there is growing concern that the pathogenic epilepsy mechanism remains poorly defined. Antiepileptic drugs are known to have endocrine side effects. Valproic acid (VPA) is commonly used as an anticonvulsant and mood-stabilizing agent in the treatment of epilepsy. In women, VPA can also lead to androgenization, menstrual disturbances, and polycystic ovaries. The incidence of polycystic ovary syndrome (PCO) increases in women with epilepsy (WWE), which appears to vary with ethnicity. Objective: This study was conducted to determine a non-invasive biomarker for early diagnosis of PCOs in WWE patients and to take preventative measures.Method and results: The study was carried out in 15 WWE women with PCO at reproductive ages (18-40 Y), monotherapy with valproic acid (VPA) and 15 healthy women as control. The women with history of diabetes, kidney and liver disease was excluded. After collecting patient serum, total RNA were extracted. We use quantitative reverse transcription PCR to identify the expression level of miRNA-222 in epileptic patients with PCOs and without it. Result and Conclusion: In accordance with previous studies on PCOs and non-PCOs women, expression level of miRNA-222 was significantly different between epileptic patients with pco and without it (p<0.05). Our result suggesting miRNA-222 as an non-invasive biomarker to screen for drug side effects and prevent the progression of its complications. Furthermore, bioinformatics analysis indicate role of miR-222 in PTEN/Akt/FOXO1 signaling pathway which may be of importance in PCOs.

کلیدواژه ها:

Epilepsy ، polycystic ovary syndrome (PCO) ، non-invasive biomarker ، miRNA-222